Steminent to Showcase Breakthrough MSC-based Therapy for Spinocerebellar Ataxia at WODC USA and ISCT 2025
BOSTON, April 24, 2025 /PRNewswire/ -- Founded in 2007, Steminent Biotherapeutics Inc. is set to present Stemchymal®, its lead investigational therapy, at the World Orphan Drug Congress (WODC) USA 2025